{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T09:55:31Z","timestamp":1790589331008,"version":"4.1.0"},"reference-count":82,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Oncolytic reovirus (ReoV) has emerged as a promising cancer immunotherapy platform because of its natural tumor tropism and immunostimulatory properties. Reovirus enters susceptible cells through receptors including junctional adhesion molecule-A and exploits oncogenic signaling and impaired antiviral responses to preferentially replicate in tumor cells. Viral replication induces apoptosis and other context-dependent forms of programmed cell death, while tumor lysis promotes antigen release and immune activation. However, reovirus monotherapy has shown limited clinical efficacy because of circulating neutralizing antibodies, heterogeneous receptor expression, stromal barriers, and the immunosuppressive tumor microenvironment. Current strategies therefore combine reovirus with chemotherapy, radiotherapy, immune checkpoint blockade, and targeted agents, although treatment outcomes remain dependent on tumor type, dose, and scheduling. Unlike previous reviews focused primarily on reovirus biology or individual combination regimens, this review examines how reovirus remodels the tumor microenvironment and critically assesses the translational limitations of combination therapy. We further discuss reverse-genetics platforms, capsid and receptor-targeting modifications, immunomodulatory transgenes, and carrier-based delivery systems. Future development will require biomarker-guided patient selection, genetically stable viral constructs, optimized systemic delivery, and prospective evidence that immune activation produces clinically meaningful benefit.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1956202","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T09:02:33Z","timestamp":1790586153000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Oncolytic reovirus: tumor-microenvironment remodeling, engineering constraints, and translational strategies"],"prefix":"10.3389","volume":"17","author":[{"given":"Rui","family":"Li","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, The First Affiliated Hospital of Henan University of Chinese Medicine","place":["Zhengzhou, China"]},{"name":"The First Clinical Medical College of Henan University of Chinese Medicine","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiafei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, The First Affiliated Hospital of Henan University of Chinese Medicine","place":["Zhengzhou, China"]},{"name":"The First Clinical Medical College of Henan University of Chinese Medicine","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiliang","family":"Cong","sequence":"additional","affiliation":[{"name":"Zhengzhou University Affiliated Cancer Hospital","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sisi","family":"Dou","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, The First Affiliated Hospital of Henan University of Chinese Medicine","place":["Zhengzhou, China"]},{"name":"The First Clinical Medical College of Henan University of Chinese Medicine","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, The First Affiliated Hospital of Henan University of Chinese Medicine","place":["Zhengzhou, China"]},{"name":"The First Clinical Medical College of Henan University of Chinese Medicine","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingjie","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, The First Affiliated Hospital of Henan University of Chinese Medicine","place":["Zhengzhou, China"]},{"name":"The First Clinical Medical College of Henan University of Chinese Medicine","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihong","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, The First Affiliated Hospital of Henan University of Chinese Medicine","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e38900","article-title":"Recent advances in nanoadjuvant-triggered STING activation for enhanced cancer immunotherapy","volume":"10","author":"Xu","year":"2024","journal-title":"Heliyon"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-92537-0","article-title":"MicroRNA 320a-3p up-regulation reduces PD-L1 expression in gastric cancer cells: an experimental and bioinformatic study","volume":"15","author":"Asghariazar","year":"2025","journal-title":"Sci Rep"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1750","article-title":"Recent progress in the battle between oncolytic viruses and tumours","volume":"5","author":"Parato","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"B4","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4939-2727-2_12","article-title":"Oncolytic viral therapy using reovirus","volume-title":"Methods Mol Biol.","author":"Thirukkumaran","year":"2015"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1172292","article-title":"Recent advances in oncolytic virus therapy for hepatocellular carcinoma","volume":"13","author":"Zhu","year":"2023","journal-title":"Front Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12539","article-title":"Altered glycan expression on breast cancer cells facilitates infection by T3 seroptype oncolytic reovirus","author":"Mohammed","year":"2021","journal-title":"Nano Lett"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/cells11111757","article-title":"Reovirus activated cell death pathways","volume":"11","author":"DeAntoneo","year":"2022","journal-title":"Cells"},{"key":"B8","doi-asserted-by":"crossref","DOI":"10.1007\/3-540-30773-7_5","article-title":"Reovirus structure and morphogenesis","volume-title":"Curr Top Microbiol.","author":"Coombs","year":"2006"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11101617","article-title":"Engineering non-human RNA viruses for cancer therapy","volume":"11","author":"Tur-Planells","year":"2023","journal-title":"Vaccines"},{"key":"B10","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","article-title":"Oncolytic virotherapy: basic principles, recent advances and future directions","volume":"8","author":"Lin","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00491-20","article-title":"Reovirus core proteins \u03bb1 and \u03c32 promote stability of disassembly intermediates and influence early replication events","volume":"94","author":"Gummersheimer","year":"2020","journal-title":"J Virol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/v13020153","article-title":"Control of capsid transformations during reovirus entry","volume":"13","author":"Gummersheimer","year":"2021","journal-title":"Viruses"},{"key":"B13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2147\/OV.S143808","article-title":"Current understanding of reovirus oncolysis mechanisms","volume":"7","author":"Phillips","year":"2018","journal-title":"Oncolytic Virotherapy"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00515-22","article-title":"The reovirus \u03c33 protein inhibits NF-\u03baB-dependent antiviral signaling","volume":"96","author":"McNamara","year":"2022","journal-title":"J Virol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20398","article-title":"Enhanced cathepsin L expression is mediated by different Ras effector pathways in fibroblasts and epithelial cells","volume":"112","author":"Collette","year":"2004","journal-title":"Int J Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032320","article-title":"Reovirus type 3 Dearing variants do not induce necroptosis in RIPK3-expressing human tumor cell lines","volume":"24","author":"van den Wollenberg","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/v8010004","article-title":"Exploring reovirus plasticity for improving its use as oncolytic virus","volume":"8","author":"Kemp","year":"2015","journal-title":"Viruses"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2015.156","article-title":"Combination therapy with reovirus and anti-PD-1 blockade controls tumor growth through innate and adaptive immune responses","volume":"24","author":"Rajani","year":"2016","journal-title":"Mol Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113219","article-title":"Past, present and future of oncolytic reovirus","volume":"12","author":"M\u00fcller","year":"2020","journal-title":"Cancers"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00178-13","article-title":"Reovirus activates a caspase-independent cell death pathway","volume":"4","author":"Berger","year":"2013","journal-title":"mBio"},{"key":"B21","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/imr.12539","article-title":"RIPK3\u2010driven cell death during virus infections","volume":"277","author":"Upton","year":"2017","journal-title":"Immunol Rev"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05979-8","article-title":"Treatment with mRNA coding for the necroptosis mediator MLKL induces antitumor immunity directed against neo-epitopes","volume":"9","author":"Van Hoecke","year":"2018","journal-title":"Nat Commun"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2025.101995","article-title":"Reovirus oncolysis and the next frontiers for this unique oncoviral immunotherapy","volume":"80","author":"Sharifi","year":"2025","journal-title":"Semin Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-10-0590","article-title":"Reovirus virotherapy overrides tumor antigen presentation evasion and promotes protective antitumor immunity","volume":"9","author":"Gujar","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"B25","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/cei.12562","article-title":"Controlled infection with a therapeutic virus defines the activation kinetics of human natural killer cells in vivo","volume":"180","author":"El-Sherbiny","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0831","article-title":"Tumor infection by oncolytic reovirus primes adaptive antitumor immunity","volume":"14","author":"Prestwich","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901074","article-title":"Reciprocal human dendritic cell\u2013natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus","volume":"183","author":"Prestwich","year":"2009","journal-title":"J Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4161\/onci.27622","article-title":"Two is better than one: Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses","volume":"3","author":"Gujar","year":"2014","journal-title":"OncoImmunology"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.695","article-title":"Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms","volume":"110","author":"Gujar","year":"2014","journal-title":"Br J Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1700435","article-title":"Oncolytic reovirus inhibits immunosuppressive activity of myeloid-derived suppressor cells in a TLR3-dependent manner","volume":"200","author":"Katayama","year":"2018","journal-title":"J Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.03070","article-title":"Deciphering the crosstalk between myeloid-derived suppressor cells and regulatory T cells in pancreatic ductal adenocarcinoma","volume":"10","author":"Siret","year":"2019","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.omto.2018.10.001","article-title":"Myelolytic treatments enhance oncolytic herpes virotherapy in models of Ewing sarcoma by modulating the immune microenvironment","volume":"11","author":"Denton","year":"2018","journal-title":"Mol Ther Oncolytics"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.7150\/thno.72853","article-title":"The landscape of cancer-associated fibroblasts in colorectal cancer liver metastases","volume":"12","author":"Giguelay","year":"2022","journal-title":"Theranostics"},{"key":"B34","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1186\/s12967-023-04281-6","article-title":"Interactions between MFAP5\u2009+\u2009fibroblasts and tumor-infiltrating myeloid cells shape the Malignant microenvironment of colorectal cancer","volume":"21","author":"Peng","year":"2023","journal-title":"J Transl Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.121269","article-title":"Oncolytic reovirus-mediated killing of mouse cancer-associated fibroblasts","volume":"610","author":"Kurisu","year":"2021","journal-title":"Int J Pharm"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2013.00231","article-title":"Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes","volume":"3","author":"Bellone","year":"2013","journal-title":"Front Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cytogfr.2020.07.007","article-title":"Tumour vasculature: Friend or foe of oncolytic viruses","volume":"56","author":"Santry","year":"2020","journal-title":"Cytokine Growth Factor Rev"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.21423","article-title":"Oncolytic reovirus inhibits angiogenesis through induction of CXCL10\/IP-10 and abrogation of HIF activity in soft tissue sarcomas","volume":"8","author":"Carew","year":"2017","journal-title":"Oncotarget"},{"key":"B39","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","article-title":"The emerging hallmarks of cancer metabolism","volume":"23","author":"Pavlova","year":"2016","journal-title":"Cell Metab"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-18-2414","article-title":"Inhibition of pyruvate dehydrogenase kinase enhances the antitumor efficacy of oncolytic reovirus","volume":"79","author":"Kennedy","year":"2019","journal-title":"Cancer Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.131203198","article-title":"Reovirus reverse genetics: Incorporation of theCATgene into the reovirus genome","volume":"98","author":"Roner","year":"2001","journal-title":"Proc Natl Acad Sci"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymeth.2011.07.002","article-title":"Reverse genetics for mammalian reovirus","volume":"55","author":"Boehme","year":"2011","journal-title":"Methods"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01411-19","article-title":"Enhanced killing of triple-negative breast cancer cells by reassortant reovirus and topoisomerase inhibitors","volume":"93","author":"Rodr\u00edguez Stewart","year":"2019","journal-title":"J Virol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2023.100743","article-title":"Improved oncolytic activity of a reovirus mutant that displays enhanced virus spread due to reduced cell attachment","volume":"31","author":"Cristi","year":"2023","journal-title":"Mol Ther Oncolytics"},{"key":"B45","doi-asserted-by":"publisher","first-page":"S175","DOI":"10.1016\/s2666-1683(21)01195-2","article-title":"Mutant reovirus with oncolytic and immune-modulatory effects in human and murine prostate cancer models","volume":"32","author":"Janssen","year":"2021","journal-title":"Eur Urol Open Sci"},{"key":"B46","doi-asserted-by":"publisher","first-page":"S181","DOI":"10.1016\/s2666-1683(21)01201-5","article-title":"Anti-tumour and immune stimulatory effects in bladder cancer of oncolytic reoviruses R124 and mutant jin-3","volume":"32","author":"Van Der Horst","year":"2021","journal-title":"Eur Urol Open Sci"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2026.201128","article-title":"Improved oncolytic and immunostimulatory activity of the spontaneous jin-3 reovirus mutant in preclinical bladder cancer models","volume":"34","author":"van de Merbel","year":"2026","journal-title":"Mol Ther Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01163-20","article-title":"Reovirus \u03c31 conformational flexibility modulates the efficiency of host cell attachment","volume":"94","author":"Diller","year":"2020","journal-title":"J Virol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00074-26","article-title":"Enhanced sialic acid engagement at physiological temperatures by reovirus \u03c31 mutants facilitates infection of breast cancer cells with low levels of high-affinity receptors","volume":"100","author":"Taal","year":"2026","journal-title":"J Virol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2024.200846","article-title":"The reovirus variant RP116 is oncolytic in immunocompetent models and generates reduced neutralizing antibodies to Type 3 Dearing","volume":"32","author":"Song","year":"2024","journal-title":"Mol Therapy: Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-018-0063-9","article-title":"Arming oncolytic reovirus with GM-CSF gene to enhance immunity","volume":"26","author":"Kemp","year":"2018","journal-title":"Cancer Gene Ther"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3390\/ph17010079","article-title":"Cytocidal effect of irradiation on gastric cancer cells infected with a recombinant mammalian orthoreovirus expressing a membrane-targeted KillerRed","volume":"17","author":"Shirasaka","year":"2024","journal-title":"Pharmaceuticals"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/v18030350","article-title":"Identification of oncolytic avian reovirus receptors in B16-F10 cells and the signaling-mediated pathways involved in viral entry","volume":"18","author":"Hsu","year":"2026","journal-title":"Viruses"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00074-22","article-title":"p17-modulated Hsp90\/Cdc37 complex governs oncolytic avian reovirus replication by chaperoning p17, which promotes viral protein synthesis and accumulation of viral proteins \u03c3C and \u03c3A in viral factories","volume":"96","author":"Huang","year":"2022","journal-title":"J Virol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3892\/ol.2021.12499","article-title":"Mesenchymal stem cell carriers enhance anti-tumor efficacy of oncolytic virotherapy (review)","volume":"21","author":"Wang","year":"2021","journal-title":"Oncol Lett"},{"key":"B56","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1186\/s12935-021-01848-5","article-title":"MSCs loaded with oncolytic reovirus: migration and in vivo virus delivery potential for evaluating anti-cancer effect in tumor-bearing C57BL\/6 mice","volume":"21","author":"Seyed-Khorrami","year":"2021","journal-title":"Cancer Cell Int"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.29955","article-title":"Mesenchymal stem cells support delivery and boost the efficacy of oncolytic reoviruses in TC\u20101 tumor cells","volume":"122","author":"Banijamali","year":"2021","journal-title":"J Cell Biochem"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107437","article-title":"Mesenchymal stem cell carriers enhance antitumor efficacy induced by oncolytic reovirus in acute myeloid leukemia","volume":"94","author":"Wang","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2025.123489","article-title":"Mesenchymal stem cell-derived small extracellular vesicles as a delivery vehicle of oncolytic reovirus","volume":"368","author":"Uno","year":"2025","journal-title":"Life Sci"},{"key":"B60","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jconrel.2024.07.079","article-title":"Small extracellular vesicles carrying reovirus, tumor antigens, interferon-\u03b2, and damage-associated molecular patterns for efficient tumor treatment","volume":"374","author":"Shuwari","year":"2024","journal-title":"J Controlled Release"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2024.110196","article-title":"Cationic liposomes overcome neutralizing antibodies and enhance reovirus efficacy in ovarian cancer","volume":"598","author":"Yang","year":"2024","journal-title":"Virology"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28450","article-title":"Lymphokine\u2010activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites","volume":"134","author":"Jennings","year":"2013","journal-title":"Int J Cancer"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1159\/000519492","article-title":"Low-intensity ultrasound as a novel strategy to improve the cytotoxic effect of oncolytic reovirus on colorectal cancer model cells","volume":"65","author":"Sharifi","year":"2022","journal-title":"Intervirology"},{"key":"B64","doi-asserted-by":"publisher","first-page":"9092","DOI":"10.1038\/s41467-024-53347-6","article-title":"Oral reovirus reshapes the gut microbiome and enhances antitumor immunity in colon cancer","volume":"15","author":"Lee","year":"2024","journal-title":"Nat Commun"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01380-19","article-title":"Breast tumor-associated metalloproteases restrict reovirus oncolysis by cleaving the \u03c31 cell attachment protein and can be overcome by mutation of \u03c31","volume":"93","author":"Fernandes","year":"2019","journal-title":"J Virol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3390\/v15071472","article-title":"Modulation of reoviral cytolysis (I): Combination therapeutics","volume":"15","author":"Mori","year":"2023","journal-title":"Viruses"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1101\/2024.09.26.24314049","article-title":"Single versus repeated intravenous oncolytic reovirus infusions: Implications for immune modulation and rationalised scheduling of therapy in hepatocellular carcinoma","volume":"158","author":"Scott","year":"2026","journal-title":"Int J Cancer"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/5837235","article-title":"The adaptive complexity of cancer","volume":"2018","author":"Derbal","year":"2018","journal-title":"BioMed Res Int"},{"key":"B69","article-title":"Research progress of reoviruses in the treatment of ovarian cancer","volume":"2","author":"Sun","year":"2021","journal-title":"Global J Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/s41596-024-00985-1","article-title":"Tutorial: Design, production and testing of oncolytic viruses for cancer immunotherapy","volume":"19","author":"Gujar","year":"2024","journal-title":"Nat Protoc"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2020.08.008","article-title":"Doxorubicin conjugation to reovirus improves oncolytic efficacy in triple-negative breast cancer","volume":"18","author":"Berry","year":"2020","journal-title":"Mol Ther Oncolytics"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-10-0054","article-title":"Two-stage phase I dose-escalation study of intratumoral reovirus type 3 Dearing and palliative radiotherapy in patients with advanced cancers","volume":"16","author":"Harrington","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noy148.032","article-title":"Phase I\/II study to evaluate the safety and clinical efficacy of atezolizumab (atezo; aPDL1) in combination with temozolomide (TMZ) and radiation in patients with newly diagnosed glioblastoma (GBM)","volume":"38","author":"Weathers","year":"2020","journal-title":"J Clin Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10365","article-title":"Enhanced cytotoxicity of reovirus and radiotherapy in melanoma cells is mediated through increased viral replication and mitochondrial apoptotic signalling","volume":"7","author":"McEntee","year":"2016","journal-title":"Oncotarget"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.20517\/2394-4722.2021.212","article-title":"Combining oncolytic virus and radiation therapy for cancer management","volume":"8","author":"Jayalie","year":"2022","journal-title":"J Cancer Metastasis Treat"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1018767","article-title":"Potentiating effect of reovirus on immune checkpoint inhibition in microsatellite stable colorectal cancer","volume":"12","author":"Augustine","year":"2022","journal-title":"Front Oncol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002096","article-title":"Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis","volume":"9","author":"Gebremeskel","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2020.09.010","article-title":"Oncolytic reovirus-mediated recruitment of early innate immune responses reverses immunotherapy resistance in prostate tumors","volume":"20","author":"Annels","year":"2021","journal-title":"Mol Ther Oncolytics"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-2251036\/v1","article-title":"Reovirus combined with a STING agonist enhances anti-tumor immunity in a mouse model of colorectal cancer","volume":"72","author":"Sugimura","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0326029","article-title":"Modulating autophagy in KRAS mutant colorectal cancer using combination of oncolytic reovirus and carbamazepine","volume":"20","author":"Shaykevich","year":"2025","journal-title":"PLoS One"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00719-w","article-title":"Therapy with oncolytic viruses: Progress and challenges","volume":"20","author":"Shalhout","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41392-025-02343-3","article-title":"Oncolytic viruses: Advanced strategies in cancer therapy","volume":"11","author":"Xiao","year":"2026","journal-title":"Signal Transduction Targeted Ther"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1956202\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T09:02:35Z","timestamp":1790586155000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1956202\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":82,"alternative-id":["10.3389\/fimmu.2026.1956202"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1956202","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"article-number":"1956202"}}